Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 11:11:636633.
doi: 10.3389/fonc.2021.636633. eCollection 2021.

Molecular Mechanisms of the Genetic Predisposition to Acute Megakaryoblastic Leukemia in Infants With Down Syndrome

Affiliations
Review

Molecular Mechanisms of the Genetic Predisposition to Acute Megakaryoblastic Leukemia in Infants With Down Syndrome

Juliane Grimm et al. Front Oncol. .

Abstract

Individuals with Down syndrome are genetically predisposed to developing acute megakaryoblastic leukemia. This myeloid leukemia associated with Down syndrome (ML-DS) demonstrates a model of step-wise leukemogenesis with perturbed hematopoiesis already presenting in utero, facilitating the acquisition of additional driver mutations such as truncating GATA1 variants, which are pathognomonic to the disease. Consequently, the affected individuals suffer from a transient abnormal myelopoiesis (TAM)-a pre-leukemic state preceding the progression to ML-DS. In our review, we focus on the molecular mechanisms of the different steps of clonal evolution in Down syndrome leukemogenesis, and aim to provide a comprehensive view on the complex interplay between gene dosage imbalances, GATA1 mutations and somatic mutations affecting JAK-STAT signaling, the cohesin complex and epigenetic regulators.

Keywords: ML–DS; TAM; Trisomy 21 (Down syndrome); acute megakaryoblastic leukemia; acute myeloid leukemia; genetic predisposition; transient myeloproliferative disorder of Down syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Schematic overview of human chromosome 21 (HSA21) and the proposed Down syndrome critical region (DSCR), along with the location of the genes discussed in this article which are suggested to be involved in the dysregulated hematopoiesis observed in individuals with trisomy 21.
Figure 2
Figure 2
Perturbation of fetal liver hematopoiesis caused by trisomy 21 and loss of full length GATA1. (A) In euploid individuals the balanced gene dosages of chromosome 21 and the presence of full length GATA1 contribute to normal fetal liver hematopoiesis. (B) In contrast trisomy 21 causes expansion of hematopoietic stem and progenitor cells (HSPC), megakaryocytic and erythroid cells via increased gene dosages. (C) When an additional GATA1 mutation, which leads to the expression of only the short isoform of GATA1 (GATA1s), is acquired immortalized megakaryocytic blasts rapidly expand at the expense of erythropoiesis. This is known as transient abnormal myelopoiesis which typically originates during fetal liver hematopoiesis.

Similar articles

Cited by

References

    1. Satgé D, Seidel MG. The Pattern of Malignancies in Down Syndrome and Its Potential Context With the Immune System. Front Immunol (2018) 9:3058. 10.3389/fimmu.2018.03058 - DOI - PMC - PubMed
    1. Hasle H. Pattern of malignant disorders in individuals with Down’s syndrome. Lancet Oncol (2001) 2:429–36. 10.1016/S1470-2045(00)00435-6 - DOI - PubMed
    1. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet (2000) 355:165–9. 10.1016/S0140-6736(99)05264-2 - DOI - PubMed
    1. Hasle H, Friedman JM, Olsen JH, Rasmussen SA. Low risk of solid tumors in persons with Down syndrome. Genet Med (2016) 18:1151–7. 10.1038/gim.2016.23 - DOI - PubMed
    1. Uffmann M, Rasche M, Zimmermann M, von Neuhoff C, Creutzig U, Dworzak M, et al. . Therapy reduction in patients with Down syndrome and myeloid leukemia: The international ML-DS 2006 trial. Blood (2017) 129:3314–21. 10.1182/blood-2017-01-765057 - DOI - PubMed

LinkOut - more resources